Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi
Authors:
- Shajahan AbduSAShajahan Abdu
- Brian GodmanBGBrian Godman
- Sahar FahmySFSahar Fahmy
- Rickard E MalmströmRMRickard E Malmström
- Lars L GustafssonLGLars L Gustafsson
- 1 February 2012
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 12 (1) , 115-124
Abstract
Pharmaceutical expenditure has risen rapidly in Abu Dhabi, resulting in policies surrounding generics. However, various circumstances will reduce potential savings, including pharmacists still being free to dispense either originator or branded generics and be fully reimbursed. To research the changes in utilization patterns of proton pump inhibitors (PPIs) and lipid-lowering drugs before and after combined reforms on generics; and subsequently, calculate potential savings based on 'best practices' among Western European countries. An uncontrolled before-and-after observational study of utilization and expenditure of PPIs, statins and ezetimibe between 2004 and 2010, as well as up to 12 months before the first generic policy, to 1 year after the second generic policy, was carried out. Utilization was converted to defined daily doses (DDDs; 2011 DDDs) and DDDs/1000 inhabitants per day. Expenditure/DDD was calculated for omeprazole and simvastatin. PPI utilization rose by 6.5-fold from 2004 to 2010, principally driven by increased utilization of patent-protected PPIs, although more recently stabilization in esomperazole utilization has occurred. Similar changes were seen for statins. Introduction of best practices would reduce PPI expenditure in 2010 by 32.8 million United Arab Emirates dirham (AED; €6.26 million) and statins by over 27 million AED (€5.15 million). Limited demand-side measures led to increased utilization of patent-protected products in Abu Dhabi following the generic reforms. Successful measures will release considerable resources.Keywords
This publication has 45 references indexed in Scilit:
- The ‘Wise List’– A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in StockholmBasic & Clinical Pharmacology & Toxicology, 2011
- Policies to Enhance Prescribing Efficiency in Europe: Findings and Future ImplicationsFrontiers in Pharmacology, 2011
- Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implicationsExpert Review of Pharmacoeconomics & Outcomes Research, 2010
- Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?Pharmaceuticals, 2010
- Initiatives to enhance renin–angiotensin prescribing efficiency in Austria: impact and implications for other countriesExpert Review of Pharmacoeconomics & Outcomes Research, 2010
- Ongoing pharmaceutical reforms in FranceApplied Health Economics and Health Policy, 2010
- Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future directionExpert Review of Pharmacoeconomics & Outcomes Research, 2009
- Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevanceExpert Review of Pharmacoeconomics & Outcomes Research, 2009
- Insight into recent reforms and initiatives in Austria: implications for key stakeholdersExpert Review of Pharmacoeconomics & Outcomes Research, 2008
- Recent National and Regional Drug Reforms in SwedenPharmacoEconomics, 2008